인쇄하기
취소

Pfizer Korea to focus on arthritis drugs as moneymaker

Published: 2003-04-22 07:00:00
Updated: 2003-04-22 07:00:00
With Pfizer and Pharmacia combining operations on April 16, Pfizer Korea seems like to concentrate its sales on Bextra, Celebrex and Xalatan as new cash cow in the current downturn in the domestic pharmaceutical industry.

"We will use the depth and experience of the Pfizer sales force to increase the already strong positions of Pharmacia in oncology, endocrinology and ophthalmology. Our unit...

Fees

- Email service daily and homepage access.
  1. $300 per month.
  2. 5 Email holders per each company.
  3. Anual contract base.
Copyright Yakup.com All rights reserved.
약업닷컴의 모든 컨텐츠는 저작권법의 보호를 받습니다. 무단 전재⋅복사⋅배포 등을 금합니다.